Abstract | OBJECTIVE: DESIGN: Open clinical trial. PATIENTS: A total of 14 patients (6 women, 8 men; mean age 57 years, range 43-67 years) were included in the study. INTERVENTION: Treatment with 90 g IVIg (30 g daily for 3 days). MAIN OUTCOME: Muscle strength, measured with dynamic dynamometry, muscle function, by means of performing the 6-minute walk test, and quality of life, analysed by means of the SF-36 questionnaire, were performed before and after treatment. RESULTS: For quality of life there was a statistically significant improvement for all but one of the 8 multi-item scales of SF-36 when comparing data before and after treatment with IVIg. The multi-item scale most improved was Vitality. There was no significant increase in muscle strength and physical performance. CONCLUSION: Data indicate that IVIg may have a clinically relevant effect, with an improvement in quality of life. The effect may be due to a decrease in an inflammatory process in the central nervous system, which earlier has been reported in patients with past- polio syndrome after IVIg treatment. Since a possible placebo effect cannot be ruled out, a randomized controlled study is needed.
|
Authors | Georgios Kaponides, Henrik Gonzalez, Tomas Olsson, Kristian Borg |
Journal | Journal of rehabilitation medicine
(J Rehabil Med)
Vol. 38
Issue 2
Pg. 138-40
(Mar 2006)
ISSN: 1650-1977 [Print] Sweden |
PMID | 16546773
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cytokines
- Immunoglobulins, Intravenous
|
Topics |
- Adult
- Aged
- Cytokines
(cerebrospinal fluid)
- Female
- Humans
- Immunoglobulins, Intravenous
(administration & dosage)
- Male
- Middle Aged
- Muscle, Skeletal
(physiopathology)
- Pilot Projects
- Postpoliomyelitis Syndrome
(immunology, physiopathology, therapy)
- Quality of Life
- Surveys and Questionnaires
- Treatment Outcome
- Walking
(physiology)
|